Nov. 02 Earnings Flash (RXRX) Recursion Pharmaceuticals Inc Reports Q3 Revenue $18.6M MT Nov. 02 Recursion Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...

Recursion (RXRX) reported third-quarter 2026 results, updated clinical trial data and extended its expected cash runway into 2029. The runway includes October offering proceeds. Cash operating expense ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

RXRX is trading in the middle of its 52-week range and above its 200-day simple moving average. Price change The price of RXRX shares has increased $0.20 since the market last closed. This is a 5.43% ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

Next quarter’s earnings estimate for RXRX is -$0.21 with a range of -$0.27 to -$0.18. The previous quarter’s EPS was -$0.22. Its overall industry beat the EPS estimate 57.80% of the time in the past ...

Processing your application Please check your inbox and click the link to confirm your subscription. There was an error sending the email Why do most enterprise AI ...

AI for science is the application of machine learning and artificial intelligence methods to accelerate research and discovery across scientific domains. It encompasses work in protein structure ...